155 related articles for article (PubMed ID: 33966646)
1. The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead.
Sampat BN
J Law Med Ethics; 2021; 49(1):10-18. PubMed ID: 33966646
[TBL] [Abstract][Full Text] [Related]
2. Realizing Public Rights Through Government Patent Use.
Kapczynski A
J Law Med Ethics; 2021; 49(1):34-38. PubMed ID: 33966648
[TBL] [Abstract][Full Text] [Related]
3. Citations in Life Science Patents to Publicly Funded Research at Academic Medical Centers.
Sampat BN; Pincus HA
Clin Transl Sci; 2015 Dec; 8(6):759-63. PubMed ID: 26728947
[TBL] [Abstract][Full Text] [Related]
4. What are the respective roles of the public and private sectors in pharmaceutical innovation?
Sampat BN; Lichtenberg FR
Health Aff (Millwood); 2011 Feb; 30(2):332-9. PubMed ID: 21289355
[TBL] [Abstract][Full Text] [Related]
5. Genome sequencing. Talks of public-private deal end in acrimony.
Marshall E
Science; 2000 Mar; 287(5459):1723-5. PubMed ID: 10755918
[No Abstract] [Full Text] [Related]
6. The human genome. Controversial from the start.
Roberts L
Science; 2001 Feb; 291(5507):1182-8. PubMed ID: 11233424
[No Abstract] [Full Text] [Related]
7. Taking the profit out of biomedical research tools.
Flores MA
Nat Biotechnol; 1999 Aug; 17(8):819-20. PubMed ID: 10429252
[TBL] [Abstract][Full Text] [Related]
8. Industry and academia in transition.
Kennedy D
Science; 2003 Nov; 302(5649):1293. PubMed ID: 14631000
[No Abstract] [Full Text] [Related]
9. Regulating Drug Prices while Increasing Innovation.
Conti RM; Frank RG; Gruber J
N Engl J Med; 2021 Nov; 385(21):1921-1923. PubMed ID: 34767322
[No Abstract] [Full Text] [Related]
10. The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses.
Wolitz RE
J Leg Med; 2019; 39(2):177-211. PubMed ID: 31503531
[TBL] [Abstract][Full Text] [Related]
11. Regulating scientific research: intellectual property rights and the norms of science.
Rai AK
Northwest Univ Law Rev; 1999; 94(1):77-152. PubMed ID: 12784815
[No Abstract] [Full Text] [Related]
12. Pricing of pharmaceuticals is becoming a major challenge for health systems.
Morgan SG; Bathula HS; Moon S
BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
[No Abstract] [Full Text] [Related]
13. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges.
Sarpatwari A; Kesselheim AS
J Law Med Ethics; 2021; 49(1):6-9. PubMed ID: 33966663
[No Abstract] [Full Text] [Related]
14. NIH severs ties with researcher who experimented on embryos.
Weiss R
Washington Post; 1997 Jan; ():A6-7. PubMed ID: 11648051
[No Abstract] [Full Text] [Related]
15. WARF's stem cell patents and tensions between public and private sector approaches to research.
Golden JM
J Law Med Ethics; 2010; 38(2):314-31. PubMed ID: 20579254
[TBL] [Abstract][Full Text] [Related]
16. Should we patent God's creation?
Peters T
Dialog; 1996; 35(2):117-32. PubMed ID: 11660577
[No Abstract] [Full Text] [Related]
17. Rat genome spurs an unusual partnership.
Marshall E
Science; 2001 Mar; 291(5510):1872. PubMed ID: 11245170
[No Abstract] [Full Text] [Related]
18. Research, innovation and politics.
Hart DM; Branscomb LM
Nature; 2000 Oct; 407(6804):561-2. PubMed ID: 11034186
[No Abstract] [Full Text] [Related]
19. Stem cell research in the U.S. after the President's speech of August 2001.
Cohen CB
Kennedy Inst Ethics J; 2004 Mar; 14(1):97-114. PubMed ID: 15250121
[No Abstract] [Full Text] [Related]
20. The anatomy of medical research: US and international comparisons.
Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
